|Ms. Helen Tuvesson Ph.D.||Pres & CEO||4.41M||N/A||1962|
|Mr. Hans Kolam||Chief Financial Officer||N/A||N/A||1951|
|Dr. Erik Vahtola||Chief Medical Officer||N/A||N/A||N/A|
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ)’s ISS Governance QualityScore as of October 1, 2022 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 1; Compensation: 10.